Editas Medicine, Inc. (EDIT)
| Market Cap | 422.02M-30.0% |
| Revenue (ttm) | n/a+20.8% |
| Net Income | n/a+68.8% |
| EPS | n/a+73.8% |
| Shares Out | 153.46M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,264,665 |
| Open | 2.71 |
| Previous Close | 2.73 |
| Day's Range | 2.66 - 2.85 |
| 52-Week Range | 1.66 - 4.33 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 4.50(+63.64%) |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About EDIT
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology. Its lead program is EDIT-401, a one-time therapy designed to reduce LDL cholesterol through the upregulation of the LDL receptor to treat hyperlipidemia. The company also develops therapies to treat Sickle cell disease and transfusion-dependent beta thalassemia; and in vivo gene editing medicines indicated for other cells and tissues. It has a research collaboration with Juno Therapeutics, Inc. to develop alpha-beta T-cell experimental medicines for the treatment of solid and liquid tumors, and autoimmune disease. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$EDIT stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in EDIT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EDIT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EDIT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
EDIT Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Intellectual property and patent related fees | $4.56M | 73.50% |
| Sublicense and license fees | $1.64M | 26.50% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New EDIT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EDIT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EDIT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $14.96M |
| XBIState Street SPDR S&P Biotech ETF | $12.09M |
| IWMiShares Russell 2000 ETF | $10.96M |
| IWOiShares Russell 2000 Growth ETF | $3.57M |
| VXFVanguard Extended Market ETF | $3.51M |
| IBBiShares Biotechnology ETF | $2.86M |
Estimated from each fund’s disclosed top holdings × AUM
EDIT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from EDIT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score